Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2008
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
Debashis Sarker, Rhoda Molife, T R Jeffrey Evans, et al.
British Journal of Cancer
|
November 9, 2022
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
David J Propper, Fangfei Gao, Mark P Saunders, et al.
Nature Communications
|
April 20, 2022
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer
Jessica K Nelson, May Zaw Thin, Theodore Evan, et al.
Plos One
|
March 28, 2014
Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets
David Britton, Yoh Zen, Alberto Quaglia, et al.
Journal of Hepatocellular Carcinoma
|
October 29, 2024
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
Ruth Plummer, Alastair Greystoke, Gregory Naylor, et al.
The Lancet. Oncology
|
June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors
Jia Liu, Anna R Minchom, Alastair Greystoke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
Udai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Nature Communications
|
September 25, 2020
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Hemant M Kocher, Bristi Basu, Fieke E M Froeling, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2008
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
Debashis Sarker, Rhoda Molife, T R Jeffrey Evans, et al.
British Journal of Cancer
|
November 9, 2022
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
David J Propper, Fangfei Gao, Mark P Saunders, et al.
Nature Communications
|
April 20, 2022
USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer
Jessica K Nelson, May Zaw Thin, Theodore Evan, et al.
Plos One
|
March 28, 2014
Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets
David Britton, Yoh Zen, Alberto Quaglia, et al.
Journal of Hepatocellular Carcinoma
|
October 29, 2024
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
Ruth Plummer, Alastair Greystoke, Gregory Naylor, et al.
The Lancet. Oncology
|
June 8, 2018
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X Zhu, Richard S Finn, Julien Edeline, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors
Jia Liu, Anna R Minchom, Alastair Greystoke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Masatoshi Kudo, Richard S Finn, Julien Edeline, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
Udai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Nature Communications
|
September 25, 2020
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Hemant M Kocher, Bristi Basu, Fieke E M Froeling, et al.
Page
of 8